Vivos Inc. (OTCQB: RDGL), a medical device company pioneering Precision Radionuclide Therapy™ (PRnT) for the treatment of cancerous tumors, is pleased to announce that it has received its State of Washington Radioactive Materials License for the manufacturing of IsoPet®.

This approval represents a significant regulatory milestone for the Company's animal health division. It clears the way for in-house production of IsoPet® at Vivos' new domestic manufacturing facility located at the Applied Process Engineering Laboratory (APEL) in Richland, Washington.